References
1. Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physicochemical properties and biological activities: E. Kobayashi, et al.; J. Antibiot. (Tokyo) 42: 1470 (1989). 2. Calphostins, novel and specific inhibitors of protein kinase C. II. Chemical structures: T. Iida, et al.; J. Antibiot. (Tokyo). 42: 1475 (1989). 3. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors: T. Tamaoki, et al.; Methods Enzymol. 201: 340 (1991). 4. Inhibition of protein kinase C by calphostin C is light-dependent: R.F. Burns, et al.; BBRC 176: 288 (1991) 5. Calphostin C, a specific protein kinase C inhibitor, activates human neutrophils: effect on phospholipase A2 and aggregation: S. Svetlov & S. Nigam; Biochim. Biophys. Acta 1177: 75 (1993). 6. Inhibition of diacylglycerol kinase by the antitumor agent calphostin C. Evidence for similarity between the active site of diacylglycerol kinase and the regulatory site of protein kinase C: C. Redman, et al.; Biochem. Pharmacol. 50: 235 (1995). 7. Calphostin C, a widely used protein kinase C inhibitor, directly and potently blocks L-type Ca channels: H.C. Hartzell & A. Rinderknecht; Am. J. Physiol. 270: C1293 (1996). 8. Calphostin C synergistically induces apoptosis with VP-16 in lymphoma cells which express abundant phosphorylated Bcl-2 protein: M. Murata, et al.; Cell. Mol. Life Sci. 53: 737 (1997). 9. Calphostin C induces selective disassembly of the Golgi complex by a protein kinase C-independent mechanism: M. Alonso, et al.; Eur. J. Cell Biol. 76: 93 (1998). 10. Growth inhibition induced by Ro 31-8220 and calphostin C in human glioblastoma cell lines is associated with apoptosis and inhibition of CDC2 kinase: M Begemann, et al.; Anticancer Res. 18: 3139 (1998) 11. Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells: D.M. Zhu, et al.; Clin. Cancer Res. 4: 2967 (1998). 12. Calphostin C is an inhibitor of contraction, but not insulin-stimulated glucose transport, in skeletal muscle: J. Ihlemann, et al.; Acta Physiol. Scand. 167: 69 (1999). 13. Pharmacokinetic features and metabolism of calphostin C, a naturally occurring perylenequinone with an- tileukemic activity: C.L. Chen, et al.; Pharm. Res. 16: 1003 (1999). 14. Potent direct inhibition of mammalian phospholipase D isoenzymes by calphostin-c: V.A. Sciorra, et al.; Biochemistry 40: 2640 (2001). 15. Calphostin C as a rapid and strong inducer of apoptosis in human coronary artery smooth muscle cells: K.D. Krueger, et al.; Int. Immunopharmacol. 13: 1751 (2003). 16. Calphostin-C induction of vascular smooth muscle cell apoptosis proceeds through phospholipase D and microtubule inhibition: X.L. Zheng, et al.; J. Biol. Chem. 279: 7112 (2004). 17. Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex: M. Lepourcelet, et al.; Cancer Cell. 5: 91 (2004). 18. Golgi complex disassembly caused by light-activated calphostin C involves MAPK and PKA: J.A. Morgado- Diaz, et al.; Tissue Cell 39: 161 (2007). 19. Killing of cancer cells by the photoactivatable protein kinase C inhibitor, calphostin C, involves induction of endoplasmic reticulum stress: A. Kaul & W.A Maltese; Neoplasia 11: 823 (2009). 20. R.K. Gandhirajan, et al.; Neoplasia 12: 326 (2010). 21. J. Zeller, et al.; Bioorg. Med. Chem. Lett. 23: 5814 (2013)USBio References
No references available
TDS
NCBI
UniProt
Tech Support
Customer Service
